Home Other Building Blocks 867331-82-6
867331-82-6,MFCD16038901
Catalog No.:AA00GU46

867331-82-6 | Tg 100801

Pack Size
Purity
Availability
Price(USD)
Quantity
  
2mg
100%
1 week  
$198.00   $139.00
- +
5mg
98%
1 week  
$447.00   $313.00
- +
10mg
98%
1 week  
$685.00   $480.00
- +
25mg
98%
1 week  
$1,320.00   $924.00
- +
50mg
98%
1 week  
$2,035.00   $1,424.00
- +
100mg
98%
1 week  
$2,987.00   $2,091.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA00GU46
Chemical Name:
Tg 100801
CAS Number:
867331-82-6
Molecular Formula:
C33H30ClN5O3
Molecular Weight:
580.0760
MDL Number:
MFCD16038901
SMILES:
Clc1ccc(cc1c1cc(C)c2c(c1)nnc(n2)Nc1ccc(cc1)OCCN1CCCC1)OC(=O)c1ccccc1
Properties
Computed Properties
 
Complexity:
848  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
42  
Hydrogen Bond Acceptor Count:
8  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
10  
XLogP3:
7  

Literature

Title: SU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration.

Journal: Molecular vision 20110101

Title: Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema.

Journal: Journal of cellular physiology 20080701

Title: Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.

Journal: Journal of medicinal chemistry 20080327

Title: Palanki MS, et al. Development of prodrug 4-chloro-3-(5-methyl-3-{-(2-pyrrolidin-1-ylethoxy)phenylamino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration. J Med Chem. 2008 Mar 27;51(6):1546-59.

Title: Doukas, John, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. Journal of Cellular Physiology (2008), 216(1), 29-37.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:867331-82-6 Molecular Formula|867331-82-6 MDL|867331-82-6 SMILES|867331-82-6 Tg 100801